Literature DB >> 8683767

Developmental renal physiology of the low birth weight pre-term newborn.

R L Chevalier1.   

Abstract

PURPOSE: The remarkable growth of the kidney and the rapid changes in renal function in the second half of gestation and early postnatal period are discussed.
MATERIALS AND METHODS: Adaptation to the extrauterine environment involves immediate postnatal natriuresis that is prolonged in the pre-term neonate, followed by the sodium retention necessary for growth. Glomerular filtration rate increases throughout the postnatal period, and it is modulated by the renin-angiotensin system and prostaglandins. Because of this, the fetus and neonate are particularly susceptible to renal injury following the administration of angiotensin converting enzyme inhibitors or nonsteroidal anti-inflammatory drugs. Renal tubular function in the neonate is characterized by reduced renal concentration and acidification ability, which can be further compromised by obstructive uropathy. Urine calcium excretion is high in the neonate, which can be aggravated by calciuric drugs, such as furosemide and glucocorticoids.
RESULTS: Reduced renal mass results in compensatory renal growth even in the fetus, a response that could prove maladaptive later in life through excessive glomerular hyperfiltration and progressive interstitial fibrosis.
CONCLUSIONS: These factors underscore the importance of attempting to maximize functional renal mass in the neonate or infant with renal impairment of any etiology.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8683767     DOI: 10.1097/00005392-199608001-00041

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  18 in total

1.  STUDY OF GLOMERULAR FUNCTIONS IN NEONATES.

Authors:  C G Wilson; P K Sarkar; Jps Mazumdar; B Bharadhwaj
Journal:  Med J Armed Forces India       Date:  2017-06-26

Review 2.  Effects of maternally administered drugs on the fetal and neonatal kidney.

Authors:  Farid Boubred; Mariella Vendemmia; Patricia Garcia-Meric; Christophe Buffat; Veronique Millet; Umberto Simeoni
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

3.  Should prenatal hydronephrosis that resolves before birth be followed postnatally? Analysis and comparison to persistent prenatal hydronephrosis.

Authors:  Patrick L Scarborough; Elizabeth Ferrara; Douglas W Storm
Journal:  Pediatr Nephrol       Date:  2015-04-01       Impact factor: 3.714

Review 4.  Clinical pharmacology of the loop diuretics furosemide and bumetanide in neonates and infants.

Authors:  Gian Maria Pacifici
Journal:  Paediatr Drugs       Date:  2012-08-01       Impact factor: 3.022

Review 5.  Development of biomarkers to optimize pediatric patient management: what makes children different?

Authors:  Jennifer Goldman; Mara L Becker; Bridgette Jones; Mark Clements; J Steven Leeder
Journal:  Biomark Med       Date:  2011-12       Impact factor: 2.851

Review 6.  Nephron number and its determinants in early life: a primer.

Authors:  Jennifer R Charlton; Caleb H Springsteen; J Bryan Carmody
Journal:  Pediatr Nephrol       Date:  2014-02-01       Impact factor: 3.714

Review 7.  Acute kidney injury in the fetus and neonate.

Authors:  Arwa Nada; Elizabeth M Bonachea; David J Askenazi
Journal:  Semin Fetal Neonatal Med       Date:  2016-12-26       Impact factor: 3.926

8.  Identification of Risk Factors for Elevated Neonatal Gentamicin Trough Concentrations.

Authors:  Jeffrey Gonzalez; John Ahern; Elizabeth Noyes; Michele Corriveau; Charles Mercier
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Mar-Apr

Review 9.  AKI and Genetics: Evolving Concepts in the Genetics of Acute Kidney Injury: Implications for Pediatric AKI.

Authors:  Kathy Lee-Son; Jennifer G Jetton
Journal:  J Pediatr Genet       Date:  2015-08-13

10.  Serum calcium values in term and late-preterm neonates receiving gentamicin.

Authors:  Arpitha Chiruvolu; William D Engle; Dorothy Sendelbach; M Denise Manning; Gregory L Jackson
Journal:  Pediatr Nephrol       Date:  2008-01-25       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.